Experts Warn Against Relaxing Drug Approval Process

Citing the University of Sydney, and the Journal Nature, ScienceDaily reports that, “The warning follows a speech to Congress last week by President Trump in which he said the US Food and Drug Administration’s drug approval process was ‘too slow and burdensome,’ and where he promised to ‘slash the restraints, not just at FDA but across our government.’” Regardless of your position on deregulation, the full paper makes a reasoned argument, and is well worth reading. In the meantime, and assuming survival of FDA as we know it, don’t hesitate to contact PDG if you need regulatory affairs consulting or assistance with a submission.

print